Medical device firm Alcyone Lifesciences has received approval from the US Food and Drug Administration (FDA) for its neuro-ventricular cannula, Alcyone MEMS Cannula (AMC).


The AMC is a dual-lumen and MRI-compatible injection and aspiration cannula, which has been developed for use in the brain.

Alcyone Lifesciences board member Richard Upton said: "I am thrilled for the Alcyone team. They are a highly talented and hard working group that has achieved this important company milestone in an efficient and skilled way."

According to the company, the AMC is not intended for implant and it has been designed for single patient use only.

Alcyone Lifesciences founder and CEO PJ Anand said: "The neuroscience community is pioneering new therapeutic agents including gene therapy, antibody and oncolytic biologic therapy that hold great promise in treating chronic CNS disorders, but unfortunately they have lacked a clinically effective technology for precise CNS delivery direct to a neurological target and for optimal bio-distribution."

The company has developed the AMC using its microelectromechanical system (MEMS) platform and it can be used with any existing commercial imaging and stereotactic system, according to Alcyone’s product development director Deep Singh.

Alcyone develops new treatment modalities for chronic neurological conditions.

Image: Alcyone MEMS Cannula. Photo: courtesy of Business Wire/ Alcyone Lifesciences, Inc.